ArticleJournal of nanobiotechnology2010
Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes.
Article in Journal of nanobiotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Poly(lactic-co-glycolic acid) nanoparticle fabrication, functionalization, and biological considerations for drug delivery.Biomicrofluidics · 2024Review
- Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.Nanomedicine (London, England) · 2024Review
- Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement.Frontiers in pharmacology · 2022Article
- Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases.Frontiers in pharmacology · 2021Review
- Cross-Platform Comparison of Therapeutic Delivery from Multilamellar Lipid-Coated Polymer Nanoparticles.Macromolecular bioscience · 2019Article
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacological reviews · 2016Review
- Lipid-based surface engineering of PLGA nanoparticles for drug and gene delivery applications.Biomaterials research · 2016Review
- Influence of cationic lipid concentration on properties of lipid-polymer hybrid nanospheres for gene delivery.International journal of nanomedicine · 2015Article
- Strategies and hurdles using DNA vaccines to fish.Veterinary research · 2014Review
- Composite nanoparticles for gene delivery.Advances in genetics · 2014Review
- Nanoparticles for retinal gene therapy.Progress in retinal and eye research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmid DNA encoding a luciferase reporter gene was complexed with each of six different hybrid nanoparticles (NPs) synthesized from mixtures of poly (D, L-lactide-co-glycolide acid) (PLGA 50:50) and the cationic lipids DOTAP (1, 2-Dioleoyl-3-Trimethyammonium-Propane) or DC-Chol {3beta-[N-(N', N'-Dimethylaminoethane)-carbamyl] Cholesterol}. Particles were 100-400 nm in diameter and the resulting complexes had DNA adsorbed on the surface (out), encapsulated (in), or DNA adsorbed and encapsulated (both). A luciferase reporter assay was used to quantify DNA expression in 293 cells for the uptake of six different NP/DNA complexes. Optimal DNA delivery occurred for 105 cells over a range of 500 ng - 10 mug of NPs containing 20-30 mug DNA per 1 mg of NPs. Uptake of DNA from NP/DNA complexes was found to be 500-600 times as efficient as unbound DNA. Regression analysis was performed and lines were drawn for DNA uptake over a four week interval. NP/DNA complexes with adsorbed NPs (out) showed a large initial uptake followed by a steep slope of DNA decline and large angle of declination; lines from uptake of adsorbed and encapsulated NPs (both) also exhibited a large initial uptake but was followed by a gradual slope of DNA decline and small angle of declination, indicating longer times of luciferase expression in 293 cells. NPs with encapsulated DNA only (in), gave an intermediate activity. The latter two effects were best seen with DOTAP-NPs while the former was best seen with DC-Chol-NPs. These results provide optimal conditions for using different hybrid NP/DNA complexes in vitro and in the future, will be tested in vivo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.